Sudarshan Pharma Industries Ltd has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The filing, dated April 6, 2026, was made to BSE Limited as part of the company's regulatory obligations.

Regulatory Compliance Certificate

The certificate was issued by KFIN Technologies Limited, which serves as the registrar and share transfer agent for sudarshan pharma industries . The document confirms compliance with SEBI (Depository and Participants) Regulations 2018 for the fourth quarter of fiscal year 2026.

Certificate Details

KFIN Technologies Limited, acting as the registrar to issue and share transfer agent, certified that details of securities dematerialized and rematerialized during Q4FY26 have been furnished to all stock exchanges where the company's shares are listed. The certificates were issued separately to both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

The certification was signed by Praveen Chaturvedi, Senior Vice President at KFIN Technologies Limited, confirming the company's adherence to regulatory requirements during the specified quarter.

Company Information

Sudarshan Pharma Industries Ltd operates from its head office located at 301, Aura Biplex, Premium Retail, Premises 7, S.V. Road, Borivali (West), Mumbai. The company secretary and compliance officer, Nirav Shah, submitted the filing to ensure regulatory compliance.

Regulatory Significance

This quarterly certificate filing represents a mandatory compliance requirement under SEBI regulations, ensuring transparency in the dematerialization and rematerialization of securities. The submission confirms that the company has maintained proper records and reporting standards as required by India's securities market regulations.

Sudarshan Pharma Industries Ltd has provided a comprehensive update on the GST inspection, search and seizure operation that concluded successfully on February 25, 2026. The operation, which commenced at its registered office on February 21, 2026, was conducted by the Goods & Service Tax Department, Mumbai, Maharashtra.

Official Communication and Updated Disclosure

Sudarshan Pharma Industries made the updated disclosure through official communication dated February 26, 2026, addressed to BSE Limited under reference number SPIL/CS/SE/2025-2026/74. This follows the initial notification made on February 22, 2026, demonstrating the company's commitment to continuous transparency and regulatory compliance under SEBI Listing Obligations.

Inspection Timeline and Conclusion

The GST inspection operation spanned five days, from February 21, 2026 to February 25, 2026. Throughout this period, company officers provided full cooperation to GST Department officials, supplying all necessary documents, information, and clarifications as requested by the authorities.

Key Findings and Compliance Status

The inspection results revealed favorable outcomes for Sudarshan Pharma Industries. According to the detailed annexure provided under SEBI circular requirements, no violations or contraventions were found attributable to the company's compliance and filings. Any liability identified was related to non-compliance by a vendor of the company, not the company's own operations.

Regulatory Framework and Authorization

Chairman & Managing Director Hemal Mehta signed the updated communication, replacing the earlier signatory Company Secretary Nirav Shah. The disclosure was made in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, which requires detailed reporting of regulatory actions.

The successful conclusion of the GST inspection with no material findings against the company reinforces Sudarshan Pharma Industries' strong compliance framework and operational integrity, providing reassurance to investors and stakeholders about the company's regulatory standing.